Announcements Trials

Browse Landscape

Phase

Status

Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Medullary 1

Interventions

Specimen Handling 218 Magnetic Resonance Spectroscopy 194 pembrolizumab 185 Carboplatin 160 Biopsy 129 Cisplatin 128 Nivolumab 119 Paclitaxel 107 Cyclophosphamide 104 Radiotherapy 99 Gemcitabine 96 Dexamethasone 86 durvalumab 83 atezolizumab 70 Rituximab 66 Radiation 64 Lenalidomide 64 Doxorubicin 63 Pemetrexed 61 Bevacizumab 58 Etoposide 56 Docetaxel 56 olaparib 50 Ipilimumab 49 Fluorouracil 48 Taxes 47 Prednisone 47 Oxaliplatin 46 Vincristine 45 Cytarabine 45

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × vandetanib × 90 days × Clear all

NCT04211337 2026-03-19

LIBRETTO-531

Eli Lilly and Company

Phase 3 Active not recruiting

291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡